Table 1 Patient characteristics
From: Accuracy and reproducibility of simplified QSPECT dosimetry for personalized 177Lu-octreotate PRRT
All patients (n = 79) | |
|---|---|
Gender, n (%) | |
Female | 36 (45.6) |
Male | 43 (54.4) |
Age at first cycle, median (range) | 60.7 (26.1–82.3) |
Site of primary tumor, n (%) | |
Small intestine | 30 (38.0) |
Pancreas | 26 (32.9) |
Adrenal glanda | 6 (7.6) |
Lung | 6 (7.6) |
Colon | 2 (2.5) |
Stomach | 1 (1.3) |
Esthesioneuroblastoma | 1 (1.3) |
Unknown | 7 (8.9) |
Metastases, n (%) | |
Liver | 66 (83.5) |
Lymph nodes | 51 (64.6) |
Bone | 29 (36.7) |
Lung | 9 (11.4) |
Otherb | 25 (31.6) |
Body size descriptors, mean ± SD (range) | |
Weight (Kg) | 72.1 ± 16.6 (42.6–121.0) |
Lean body weight (Kg) | 52.4 ± 9.9 (35.4–81.2) |
Body surface area (m2) | 1.8 ± 80.2 (1.4–2.5) |
eGFR (ml/min/1.73 m2), mean ± SD (range) | 86.3 ± 22.2 (42.0–154.1) |
Number of cycles, n (%) | |
1 | 8 (10.1) |
2 | 6 (7.6) |
3 | 16 (20.3) |
4 | 38 (48.1) |
5 | 3 (3.8) |
6 | 6 (7.6) |
7 | 1 (1.3) |
8 | 1 (1.3) |
Type of cycles, n (%) | |
Empiric only | 23 (29.1) |
Personalized only | 45 (57.0) |
Mixed | 11 (13.9) |